Midazolam +/- GDC 0032 in patients with advanced solid tumours

Trial Profile

Midazolam +/- GDC 0032 in patients with advanced solid tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2013

At a glance

  • Drugs Taselisib (Primary) ; Midazolam
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 17 Dec 2013 New trial record
    • 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top